Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Thoracic Paravertebral Block with Local Anesthetic
The First People's Hospital of Lianyungang
Pulmonary Nodules
1 trial -
Tianqi Pingchan Granule
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Levodopa-Induced Dyskinesia
1 trial -
Ticagrelor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Brain Disease
1 trial -
Ticagrelor monotherapy
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial -
Tislelizumab combined with Lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Initially Unresectable Hepatocellular Carcinoma
1 trial -
To withdraw NSAIDs therapy
The First People's Hospital of Lianyungang
Axial Spondyloarthritis
1 trial -
Topical compound tripterygium
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Active Rheumatoid Arthritis
1 trial -
Topical diclofenac sodium gel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hand Osteoarthritis
1 trial -
Total glucosides of paeony & Acitretin Capsules
The First People's Hospital of Lianyungang
Psoriasis
1 trial -
Traditional Chinese Medicine treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Frail Elderly Patients
1 trial -
Tramadol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hip Fractures
1 trial -
Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Hospital Authority, Hong Kong
Rotator Cuff Tears
1 trial -
Tranexamic acid (TXA)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Blood Loss
1 trial -
Transesophageal echocardiography
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Critically Ill
1 trial -
Trolamine (Biafine)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Dermatitis
1 trial -
Tumor Specific Antigen-loaded Dendritic Cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tumor Gastric
1 trial -
UC-MSCs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
2019 Novel Coronavirus Pneumonia
1 trial -
UE
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
Ulinastatin
The First People's Hospital of Lianyungang
Acute Respiratory Distress Syndrome
1 trial -
Ulinastatin and Thymosin Ξ±1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aortic Dissection
1 trial -
Ultra low dose chest computed tomography (ULDCT)
Hospital Authority, Hong Kong
Tuberculosis, Pulmonary
1 trial -
Ultrasound Elastography
Jazz Pharmaceuticals Ireland Limited
Bone Marrow Transplant Complications
1 trial -
Umbilical cord serum eyedrops
Hospital Authority, Hong Kong
Recurrent Corneal Erosion
1 trial -
Unfractionated heparin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary PCI
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources